



S&H Form: (01/03)

**REPLY/AMENDMENT
FEE TRANSMITTAL**

Attorney Docket No.	1546.1007
Application Number	09/995,829
Filing Date	November 29, 2001
First Named Inventor	Ji-Won YOON, et al.
Group Art Unit	1648
Examiner Name	Myron G. Hill

AMOUNT ENCLOSED

0.00

RECEIVED
DEC 30 2003
TECH CENTER 1600/2900**FEE CALCULATION (fees effective 01/01/03)**

CLAIMS AS AMENDED	Claims Remaining After Amendment	Highest Number Previously Paid For	Number Extra	Rate	Calculations
TOTAL CLAIMS	7	- 20 =	0	X \$ 18.00 =	\$.00
INDEPENDENT CLAIMS	2	- 3 =	0	X \$ 84.00 =	.00

Since an Official Action set an original due date December 24, 2003, petition is hereby made for an extension to cover the date this reply is filed for which the requisite fee is enclosed (1 month (\$110); 2 months (\$410); 3 months (\$930); 4 months (\$1,450); 5 months (\$1,970)):

If Notice of Appeal is enclosed, add (\$320.00)

If Statutory Disclaimer under Rule 20(d) is enclosed, add fee (\$110.00)

Information Disclosure Statement (Rule 1.17(p)) (\$180.00)

Total of above Calculations =

\$.00

Reduction by 50% for filing by small entity (37 CFR 1.9, 1.27 & 1.28)

TOTAL FEES DUE =

\$.00

(1) If entry (1) is less than entry (2), entry (3) is "0".

(2) If entry (2) is less than 20, change entry (2) to "20".

(4) If entry (4) is less than entry (5), entry (6) is "0".

(5) If entry (5) is less than 3, change entry (5) to "3".

METHOD OF PAYMENT

- ☐ Check enclosed as payment.
- ☐ Charge "TOTAL FEES DUE" to the Deposit Account No. below.
- ☒ No payment is enclosed and no charges to the Deposit Account are authorized at this time (unless specifically required to obtain a filing date).

GENERAL AUTHORIZATION

- ☒ If the above-noted "AMOUNT ENCLOSED" is not correct, the Commissioner is hereby authorized to credit any overpayment or charge any additional fees necessary to:
- | | |
|----------------------|--------------------|
| Deposit Account No. | 19-3935 |
| Deposit Account Name | STAAS & HALSEY LLP |
- ☒ The Commissioner is also authorized to credit any overpayments or charge any additional fees required under 37 CFR 1.16 (filing fees) or 37 CFR 1.17 (processing fees) during the prosecution of this application, including any related application(s) claiming benefit hereof pursuant to 35 USC § 120 (e.g., continuations/divisionals/CIPs under 37 CFR 1.53(b) and/or continuations/divisionals/CPAs under 37 CFR 1.53(d)) to maintain pendency hereof or of any such related application.

SUBMITTED BY: STAAS & HALSEY LLP

Typed Name Darleen J. Stockley

Reg. No. 34,257

Signature

Darleen J. Stockley

Date

December 24, 2003

©2003 Staas, & Halsey LLP



Docket No.: 1546.1007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Ji-Won YOON, et al.

Serial No. 09/995,829

Group Art Unit: 1648

Confirmation No. 9726

Filed: November 29, 2001

Examiner: Myron G. Hill

For: RECOMBINANT VACCINIA INCORPORATED WITH GENE CODING GLUTAMIC ACID
DECARBOXYLASE AND VACCINE FOR PREVENTING TYPE 1 DIABETES MELLITUS
COMPRISING THE SAME

RECEIVED
DEC 30 2003
TECH CENTER 1600/2900

AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the Office Action mailed September 24, 2003, and having a period for response set to expire on December 24, 2003.

The following amendments and remarks are respectfully submitted. Reconsideration of the claims is respectfully requested.